Cargando…
Current view on ductal carcinoma in situ and importance of the margin thresholds: A review
Ductal carcinoma in situ (DCIS) is a heterogeneous group of diseases that differ in biology and clinical behaviour. Until 1980, DCIS represented less than 1% of all breast cancer cases. With the increased utilization of mammography, DCIS now accounts for 15% to 25% of newly diagnosed breast cancer c...
Autores principales: | Van Cleef, A., Altintas, S., Huizing, M., Papadimitriou, K., Van Dam, P., Tjalma, W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Universa Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286860/ https://www.ncbi.nlm.nih.gov/pubmed/25593696 |
Ejemplares similares
-
Benchmarking and audit of breast units improves quality of care
por: van Dam, P.A., et al.
Publicado: (2013) -
In silico pathway analysis in cervical carcinoma reveals potential new targets for treatment
por: van Dam, Peter A., et al.
Publicado: (2015) -
Low CD10 mRNA Expression Identifies High-Risk Ductal Carcinoma In Situ (DCIS)
por: Toussaint, Jérôme, et al.
Publicado: (2010) -
The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives
por: Papadmitriou, K., et al.
Publicado: (2015) -
The smooth and bumpy road of trastuzumab administration: from intravenous (IV) in a hospital to subcutaneous (SC) at home
por: Tjalma, WAA, et al.
Publicado: (2017)